di , 24/10/2023

WASHINGTON–(BUSINESS WIRE)–Altoida, a pioneer in developing digital biomarkers of neurological disease using augmented reality (AR) and machine learning (ML), today announced results from a 188-participant study demonstrating its novel digital cognitive and functional assessment identified participants with mild cognitive impairment.

The Altoida digital cognitive assessment is a research device based on AR and ML that simulates conducting activities of daily living, providing an objective measure of cognitive and functional abilities in approximately 10 minutes, compared to pen-and-paper neuropsychological tests that take approximately 60-90 minutes.

Altoida’s digital cognitive assessment also reported correlation with standard neuropsychological tests such as the Mini-Mental State Examination (MMSE), Free and Cued Selective Reminding Test (FCSRT) and the Trail Making Test (TMT).

“Digital biomarkers are increasingly utilized as exploratory endpoints and screening tools for inclusion in clinical trials. Digital cognitive assessments offer the potential to facilitate frequent and unbiased measurements of cognitive functional status, without the need of a trained rater,” said Marc Jones, CEO, Altoida. “We’re excited to report new study data showing Altoida’s digital cognitive assessment correlating with MMSE and other neuropsychological tests, and we look forward to expanding our research to other scales.”

Conducted as a dual-center, cross-sectional cohort study, 188 participants were enrolled from the Hospital Clinic Barcelona and the Barcelona-Beta Brain Research Center. Participants received a neurological evaluation, a neuropsychological test battery, and Altoida’s digital cognitive assessment. Participants were classified according to their clinical status as cognitively normal or as having mild cognitive impairment. The study evaluated the correlation between Altoida’s digital cognitive assessment and standard neuropsychological tests, including: the Mini-Mental State Examination (MMSE) – the Free and Cued Selective Reminding Test (FCSRT) – the Trail Making Test (TMT).

Altoida’s digital cognitive assessment provides a Digital Neuro-Signature (DNS-MCI) score correlated with classical neuropsychological tests that are commonly used as a battery when evaluating patients in clinical research and clinical practice. Using DNS-MCI<50 and MMSE<27 as patient classifier led to results that are mostly overlapping in high scores, with lower agreement on lower scores.

In addition, Altoida has been a key member of the Digital Health Measurement Collaborative Community (DATAcc) by DiMe’s Alzheimer’s Disease & Related Dementias (ADRD) project team, which recently released a new resource to guide the work of clinicians and researchers and leveraged digital tools for ADRD patients. DATAcc by DiMe’s Library of Digital Measurement Products for ADRD is an invaluable resource for researchers and clinicians in the field who are assessing the available options for measurement in this population.

“We were proud to work with Altoida on the development of the new ADRD evidence library and are excited to introduce this new tool to the world to help define important measurement parameters for patients, their care partners, and physicians,” said Piper Fromy, ADRD project head, Digital Medicine Society (DiMe). “DiMe’s pre-competitive collaborations provide unique insights into ways to improve existing digital measures, develop new ones, and ultimately drive improvements and efficiencies in the emerging world of digital ADRD research.”

About Altoida

Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine.



Kimberly Ha

KKH Advisors